June 1, 2024
Renal cell carcinoma (RCC) primarily affects individuals aged 60 to 70 years, with men being twice as likely as women to develop the disease. Accounting for 3% of all adult cancers, RCC comprises multiple histological subtypes. Due to the asymptomatic nature of early-stage RCC, misdiagnosis and inadequate screening methods, over 50% of RCC cases are detected incidentally, and approximately 30% of patients are diagnosed with metastatic RCC. Recent advancements in the development of targeted therapies and immunotherapies to treat cancer warrant the need for an effective preclinical model with an intact and functional immune system, enabling the study of therapy-driven immune responses and tumor-induced immunosuppression.1 The Renca cell line, originating from a spontaneous renal adenocarcinoma of Balb/c mice, is a highly aggressive renal cancer cell line particularly valuable for evaluating novel immunotherapies, making it an essential tool in RCC research.2
